"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03819296","Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Melanoma or Genitourinary Cancer",,"Not yet recruiting","No Results Available","Clinical Stage 0 Cutaneous Melanoma AJCC v8|Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage IA Cutaneous Melanoma AJCC v8|Clinical Stage IB Cutaneous Melanoma AJCC v8|Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage IIA Cutaneous Melanoma AJCC v8|Clinical Stage IIB Cutaneous Melanoma AJCC v8|Clinical Stage IIC Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Colitis|Diarrhea|Malignant Genitourinary System Neoplasm|Pathologic Stage 0 Cutaneous Melanoma AJCC v8|Pathologic Stage I Cutaneous Melanoma AJCC v8|Pathologic Stage IA Cutaneous Melanoma AJCC v8|Pathologic Stage IB Cutaneous Melanoma AJCC v8|Pathologic Stage II Cutaneous Melanoma AJCC v8|Pathologic Stage IIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8","Other: Best Practice|Other: Biospecimen Collection|Procedure: Endoscopic Procedure|Procedure: Fecal Microbiota Transplantation|Biological: Infliximab|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Biological: Vedolizumab","Incidence of adverse events (AEs)|Incidence of toxicities (Project 3)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","800","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018-0383|NCI-2018-03437|P30CA016672","February 15, 2020","July 1, 2022","July 1, 2022","January 28, 2019",,"February 6, 2020","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03819296"
2,"NCT02728830","A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers",,"Active, not recruiting","No Results Available","Gynecologic Neoplasms|Epithelial Ovarian Cancer|Uterine Endometrial Cancer|Fallopian Tube Cancer|Peritoneal Cancer","Drug: Pembrolizumab","Fold change in tumor Immune Infiltrates|Toxicity Profile: Frequency and severity of adverse events as assessed by CTCAE","AA Secord|Merck Sharp & Dohme Corp.|Duke University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00068544","June 2016","January 2019","April 2020","April 5, 2016",,"December 23, 2019","Duke Cancer Institute, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02728830"
3,"NCT03224871","UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.",,"Completed","No Results Available","METASTATIC NON-SMALL CELL LUNG CANCER","Drug: Intralesional IL-2|Drug: Nivolumab|Drug: Pembrolizumab|Radiation: Radiotherapy","Dose limiting toxicity (DLT)|Disease free survival","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1032095|UCDCC#269","August 11, 2017","January 10, 2020","January 10, 2020","July 21, 2017",,"April 7, 2020","UC Davis Medical Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03224871"
4,"NCT03197389","Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.",,"Completed","No Results Available","Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Negative Neoplasm","Drug: Pembrolizumab","PD-1 expression|Increase in the amount of TILs|PD-L1 expression","Universitaire Ziekenhuizen Leuven","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MK 3475-318","January 18, 2018","March 31, 2020","March 31, 2020","June 23, 2017",,"April 20, 2020","University Hospitals Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT03197389"
5,"NCT03686202","Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy","MET4-IO","Recruiting","No Results Available","All Solid Tumors","Biological: MET-4","Cumulative relative abundance of immunotherapy-responsiveness associated species at day 12 of MET-4|Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains between baseline and approximately day 12|Number of participants with treatment-related adverse events assessed by CTCAE v.5.0|Cumulative relative abundance of immunotherapy-responsiveness associated species at later MET-4 or control time points (approximately 24 weeks and/or 1-2 weeks following the end of treatment).|Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains between baseline and later MET-4 or control timepoints (approximately 24 weeks and/or 1-2 weeks following the end of treatment)|Bacterial taxonomic diversity between baseline and follow-up samples","University Health Network, Toronto|NuBiyota","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","65","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MET4-IO-001","November 30, 2018","December 1, 2020","December 1, 2023","September 26, 2018",,"May 5, 2020","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03686202"
6,"NCT04130763","Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1",,"Recruiting","No Results Available","Gastrointestinal System Cancer","Biological: FMT capsule","Objective Response Rate (ORR)|The safety of FMT capsule (prior to the first anti-PD-1 immunotherapy treatment)|Change in T-cells Composition|Change in subsets of specific immune system|Change in subsets of non-specific immune system|Function of T-cells|Association of anti-PD-1 response with gut microbiota|Safety evaluation (from the beginning of the first anti-PD-1 immunotherapy treatment to the end of study)","Peking University","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XBI-302CT1001","December 2019","October 2020","October 2020","October 17, 2019",,"December 24, 2019","Beijing Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04130763"
7,"NCT04006522","89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma",,"Active, not recruiting","No Results Available","Renal Cell Carcinoma","Drug: 89Zr-DFO-Atezolizumab|Procedure: Positron Emission Tomography/Computed Tomography","Correlation between 89Zr-DFO-Atezolizumab and PD-L1|Correlation between 89Zr-DFO-Atezolizumab and anti-PD1/PD-L1 therapy","Orhan Kemal Oz|University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU-2019-0714","October 2, 2019","July 15, 2024","July 15, 2025","July 5, 2019",,"April 21, 2020","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04006522"
